aFrançois Rabelais University of Tours bCNRS, UMR 7292 'GICC' University of Tours cLaboratory of Pharmacology-Toxicology, University Hospital of Tours dLaboratory of Immunology eDepartment of Nephrology and Clinical Immunology, Tours, France.
Pharmacogenet Genomics. 2014 Jan;24(1):26-34. doi: 10.1097/FPC.0000000000000017.
Polyclonal antithymocyte globulins (ATG) have been used in transplantation for several decades, but the sources of the interindividual variability of their effect are poorly understood. An influence of the FCGR3A-158V/F genetic polymorphism on the horse ATG concentration-effect relationship was reported in kidney transplant patients. The objective of the present study was to confirm the influence of the FCGR3A polymorphism on the extent of lymphocyte depletion in kidney transplant patients treated with rabbit antithymocyte globulin (r-ATG).
Of the 194 transplant patients treated with r-ATG between 1998 and 2002 in our institution, 69 patients were eligible and included in this retrospective study. Biomarkers of response were CD3 and CD4 counts. Dose-effect data were analyzed using a population approach, and a two-compartment turnover model with stimulation of lymphocyte 'output'. Since r-ATG concentrations were not available, a K-PD model was used. The influence of FCGR3A genotype on estimated parameters was investigated.
The r-ATG infusion rate leading to a 50% stimulation of CD3+ output (EDK(50)), which is inversely related to patient sensitivity to r-ATG treatment, decreased with the number of V alleles (P=0.0016).
The genetic polymorphism of FCGR3A influences r-ATG effect on CD3 count in kidney transplant patients, those with the V allele being more sensitive to antilymphocyte serum. These results also suggest that r-ATG act, at least in part, by antibody-dependent cellular cytotoxicity.
多克隆抗胸腺细胞球蛋白(ATG)在移植中已经使用了几十年,但对其作用个体间差异的来源知之甚少。有报道称,FCGR3A-158V/F 遗传多态性对肾移植患者的马 ATG 浓度-效应关系有影响。本研究的目的是确认 FCGR3A 多态性对接受兔抗胸腺细胞球蛋白(r-ATG)治疗的肾移植患者淋巴细胞耗竭程度的影响。
在我们机构,1998 年至 2002 年间接受 r-ATG 治疗的 194 例移植患者中,有 69 例符合条件并纳入本回顾性研究。反应的生物标志物为 CD3 和 CD4 计数。使用群体方法分析剂量-效应数据,并采用刺激淋巴细胞“输出”的两室转化模型。由于 r-ATG 浓度不可用,因此使用了 K-PD 模型。研究了 FCGR3A 基因型对估计参数的影响。
导致 CD3+输出刺激 50%的 r-ATG 输注率(EDK(50)),与患者对 r-ATG 治疗的敏感性呈反比,随着 V 等位基因的数量而降低(P=0.0016)。
FCGR3A 的遗传多态性影响肾移植患者 r-ATG 对 CD3 计数的作用,携带 V 等位基因的患者对抗淋巴细胞血清更敏感。这些结果还表明,r-ATG 至少部分通过抗体依赖性细胞毒性起作用。